axsome.com
US medical affairs
This website is intended for US healthcare professionals only.

congress
presentations

CHEST 2024

Boston, MA
October 6-9, 2024

PDF screenshot

Solriamfetol | Excessive Daytime Sleepiness

Solriamfetol and Cognitive Function in Obstructive Sleep Apnea With Excessive Daytime Sleepiness and Impaired Cognition Stratified by Primary Airway Therapy Adherence: SHARP
view/download

This site is intended for registered attendees of the respective Congress.
This site contains scientific presentations on investigational products and/or investigational uses of approved products for Axsome or its partners sponsored studies.
The safety and efficacy of investigational products and/or investigational uses of approved products has not been established and such investigational products/uses have not and may not be approved for marketing by any health authority.
Marketing authorization, approval status, and prescribing information for approved products varies by country. Please seek further details from the health authority in your country such as approved product labeling.

AXSOME and its logos are trademarks or registered trademarks of Axsome Therapeutics, Inc. or its affiliates. Other trademarks are property of their respective owners.

© 2023 Axsome Therapeutics, Inc. All rights reserved. One World Trade Center, 22nd Floor, New York, NY 10007 info@axsome.com